Previous 10 | Next 10 |
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX ® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced preliminary unaudited fourth quarter 2021 financial and operational results. ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the Stephens Annual Investment Conference in Nashville, Tennes...
Pulse Biosciences, Inc. (PLSE) Q3 2021 Earnings Conference Call Nov 15, 2021 04:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President & Chief Executive Officer Ed Ebbers - Executive Vice President, General Manager of Dermatology Sandy Gardiner - Execut...
Pulse Biosciences (NASDAQ:PLSE): Q3 GAAP EPS of -$0.48 beats by $0.05. Revenue of $574M beats by $573.81M. Press Release For further details see: Pulse Biosciences EPS beats by $0.05, beats on revenue
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the third quarter of 2021. Recent Highlights Achie...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that members of management will present at the Stifel 2021 Virtual Healthcare Conference o...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter of 2021 after market close on Monday, November 15, 2021. Company manag...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX ® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment of Mitchell E. Levinson to the newly created role of Chief Strate...
Pulse Biosciences, Inc. (PLSE) Q2 2021 Earnings Conference Call August 09, 2021 04:30 PM ET Company Participants Philip Taylor - Investor Relations Darrin Uecker - President & Chief Executive Officer, Ed Ebbers - Executive Vice President, General Manager of Dermatology Sandy Gardiner - Ex...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the second quarter of 2021. Recent Highlights Cell...
News, Short Squeeze, Breakout and More Instantly...
Pulse Biosciences Inc Company Name:
PLSE Stock Symbol:
NASDAQ Market:
Pulse Biosciences Inc Website:
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, announced today the closing of its rights offering and the fi...
2024-06-25 21:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-15 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...